参附注射液治疗晚期肺癌气虚证的临床研究  

Clinical research on treating the Qixu syndrome of advanced cancer with the Shenfu injection

作　　者：杨万全[1] 王恳[1] 

机构地区：[1]四川省中西医结合医院,四川成都610041

出　　处：《中医临床研究》2016年第8期12-14,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察参附注射液治疗晚期肺癌气虚证的临床疗效。方法:将符合标准的病例共60例,采用随机数字法分为治疗组与对照组,每组各30例,对照组予中医基础抑瘤治疗、对症治疗及营养支持,治疗组在对照组的基础上予静滴参附注射液治疗,治疗周期结束时观察两组患者的气虚证症状总积分、生存质量评分、细胞免疫功能及毒副作用情况,评价参附注射液治疗晚期肺癌气虚证的临床疗效。结果:治疗组在改善患者的气虚证症状、提高生存质量、增强免疫功能方面均优于对照组(P<0.05),两组均未出现明显的毒副作用(P>0.05)。结论:参附注射液能对晚期肺癌患者的气虚证有较好的临床疗效,安全性好,值得推广使用。Objective To observe clinical efficacy of the Shenfu injection on advanced cancer of the Qixu syndrome. Methods： 60cases were randomly divided into the treatment group and the control group, 30 cases in each group. The control group was treated by basicTCM, symptomatic treatment and nutritional support; the treatment group was given the Shenfu injection more. In treatment, symptomsof deficiency points, survival quality, cellular immune function and side effects in patients were observed, in order to evaluate the clinicaleffects with the Shenfu injection on advanced cancer of the Qixu syndrome. Results： In the treatment group, Qixu symptoms, the qualityof life and the immune function which improved were better （P〈0.05）, and the patients had no obvious side effects （P〉0.05）. Conclusion：The Shenfu injection can have a good clinical effect on Qixu syndrome in patients with advanced lung cancer, which is safe and worthy ofpopularization.

关 键 词：参附注射液 气虚证 肺癌 中药治疗 

分 类 号：R322.35[医药卫生—人体解剖和组织胚胎学]